Clozapine activates AMP-activated protein kinase (AMPK) in C2C12 myotube cells and stimulates glucose uptake

Life Sciences

Volumn 87, Issue 1-2, 2010, Pages 42-48

  Kim, Ji Hae ^a   Lee, Jung Ok ^a   Lee, Soo Kyung ^a   Jung, Jin Hee ^a   You, Ga Young ^a   Park, Sun Hwa ^a   Park, Munho ^b   Kim, Sang Dae ^b   Kim, Hyeon Soo ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

AMPK; C2C12 myotubes; Calcium; CaMKK; Clozapine

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CLOZAPINE; DEOXYGLUCOSE; EDETIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; MOUSE; MYOTUBE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CELL LINE; CLOZAPINE; GLUCOSE; MICE; MUSCLE FIBERS, SKELETAL; PHOSPHORYLATION; SCINTILLATION COUNTING;

EID: 77953961746     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.05.017     Document Type: Article

References (41)

1. Bai Y.M., Lin C.C., Chen J.Y., Lin C.Y., Su T.P., Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. The American Journal of Psychiatry 2006, 163:1276-1279.
2. Bai Y.M., Chen J.Y., Chen T.T., Lin C.Y., Chou P., Su T.P., Lin C.C. Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. Schizophrenia Research 2009, 108:122-126.
3. Cheng C.Y., Hong C.J., Tsai S.J. Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c mice. Life Sciences 2005, 76:2269-2273.
4. Ciapparelli A., Dell'Osso L., Bandettini di Poggio A., Carmassi C., Cecconi D., Fenzi M., Chiavacci M.C., Bottai M., Ramacciotti C.E., Cassano G.B. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. The Journal of Clinical Psychiatry 2003, 64:451-458.
5. Crute B.E., Seefeld K., Gamble J., Kemp B.E., Witters L.A. Functional domains of the alpha1 catalytic subunit of the AMP-activated kinase. The Journal of Biological Chemistry 1993, 273:35347-35354.
6. Eder-Ischia U., Ebenbichler C., Fleischhacker W.W. Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Essential Psychopharmacology 2005, 6:112-117.
7. Fadel J., Bubser M., Deutch A.Y. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. The Journal of Neuroscience 2002, 22:6742-6746.
8. Frye M.A., Ketter T.A., Altshuler L.L., Denicoff K., Dunn R.T., Kimbrell T.A., Cora-Lacatelli G., Post R.M. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. Journal of Affective Disorders 1998, 48:91-104.
9. Fryer L.G., Patel A.P., Carling D. The anti-diabetic drugs Rosglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. The Journal of Biological Chemistry 2002, 277:25226-25232.
10. Glatt C.E., Snaoman A.M., Sibley D.R., Snyder S.H. Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile. Molecular Medicine 1995, 1:398-406.
11. Hardie D.G. The AMP-activated protein kinase pathway-new players upstream and downstream. Journal of Cell Science 2004, 117:5479-5487.
12. Hardie D.G., Carling D., Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?. Annual Review of Biochemistry 1998, 67:821-855.
13. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Letters 2003, 546:113-120.
14. Hawley S.A., Gadalla A.E., Olsen G.S., Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002, 51:2420-2425.
15. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., UDD L., Makela T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Journal of Biology 2003, 2:28.
16. Hong S.P., Momcilovic M., Carlson M. Function of mammalian LKB1 and Ca2+/calmodulin-dependnet protein kinase kinase alpha as Snf1-activating kinases in yeast. The Journal of Biological Chemistry 2005, 280:21804-21809.
17. Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R., Witters L.A. The ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. The Journal of Biological Chemistry 2005, 280:29060-29066.
18. Kahn B.B., Aliquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 2005, 1:15-25.
19. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacology Bulletin 1988, 24:62-67.
20. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., Kim Y.S. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Letters 2004, 560:115-119.
21. Kim M.S., Park J.Y., Namkoong C., Jang P.G., Ryu J.W., Song H.S., Yun J.Y., Namkoong I.S., Han J., Park I.S., Lee I.K., Viollet B., Youn J.H., Lee H.K., Lee K.U. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Natural Medicines 2004, 10:727-733.
22. Kim S.F., Huang A.S., Snowman A.M., Teuscher C., Snyder S.H. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:3456-3459.
23. Lamberti J.S., Costea G.O., Olson D., Crilly J.F., Maharaj K., Tu X., Groman A., Dietz M.B., Bushey M.P., Olivares T., Wiener K. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. The Journal of Clinical Psychiatry 2005, 66:900-906.
24. Meltzer H.Y., Cola P.A., Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996, 15:395-405.
25. Mendes L.S., Collins S.P. The effects of the atypical antipsychotics clozapine, remoxipride and risperidone on the contractile characteristics of rat skeletal muscle in vitro. Pharmacological Research 1997, 36:457-461.
26. Naumenko N.V., Malomuzh A.I., Khairova R.A., Zefirov A.L., Urazaev AKh Pharmacological parameters of muscarinic cholinoreceptors in skeletal muscles. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk 2002, 88:619-626.
27. Ness-Abramof R., Apovian C.M. Drug-induced weight gain. Drugs of Today 2005, 41:547-555.
28. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 2002, 59:337-345.
29. Nguyen Q.T., Miledi R. Inhibition of skeletal muscle nicotinic receptors by the atypical antipsychotic clozapine. Neuropharmacology 2002, 42:662-669.
30. Raeder M.B., Fernø J., Vik-Mo A.O., Steen V.M. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?. Molecular and Cellular Biochemistry 2006, 289:167-173.
31. Reynolds G.P., Hill M.J., Kirk S.L. The 5-HT2C receptor and antipsychotic induced weight gain-mechanisms and genetics. Journal of Psychopharmacology 2006, 20:15-18.
32. Scheen A.J., De Hert M.A. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes & Metabolism 2007, 33:169-175.
33. Bruce C.R., Smith A.C., Dyck D.J. AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysin in contracting rat soleus muscle. Journal of Cellular Physiology 2005, 565(pt2):537-546.
34. Spiegelman B.M., Flier J.S. Obesity and the regulation of energy balance. Cell 2001, 104:531-543.
35. Stein S.C., Woods A., Jones N.A., Davison M.D., Carling D. The regulation of AMP-activated protein kinase by phosphorylation. The Biochemical Journal 2000, 345:437-443.
36. Theisen F.M., Cichon S., Linden A., Martin M., Remschmidt H., Hebebrand J. Clozapine and weight gain. The American Journal of Psychiatry 2001, 158:816.
37. Theisen F.M., Gebhardt S., Bromel T., Otto B., Heldwein W., Heinzel-Gutenbrunner M., Krieg J.C., Remschmidt H., Tschop M., Hebebrand J. A prospective study of serum ghrelin levels in patients treated with clozapine. Journal of Neural Transmission 2005, 112:1411-1416.
38. Tovey E., Rampes H., Livingstone C. Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. Journal of Psychopharmacology 2005, 19:207-210.
39. Vestri H.S., Maianu L., Moellering D.R., Garvey W.T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32:765-772.
40. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G.D., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current Biology 2003, 13:2004-2008.
41. 2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes 2004, 53:330-335.